

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2007 (07.09.2007)

PCT

(10) International Publication Number
WO 2007/099117 A1

(51) International Patent Classification:

C07F 9/165 (2006.01) **A61P 29/00** (2006.01)
A61K 31/6615 (2006.01) **A61P 37/00** (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2007/051896

(22) International Filing Date:

28 February 2007 (28.02.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

MI2006A 000366 1 March 2006 (01.03.2006) IT

(71) Applicant (for all designated States except US): **C4T S.C. a r.l.** [IT/IT]; Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRECCIA, Perla** [IT/IT]; C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT). **ANGELI, Francesca** [IT/IT]; C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT). **COLIZZI, Vittorio** [IT/IT]; C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT). **PINZA, Mario** [IT/IT];

C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT). **POCCIA, Fabrizio** [IT/IT]; C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT). **TOPAI, Alessandra** [IT/IT]; C4T S.C. a r.l., Via della Ricerca Scientifica s.n.c., Edificio PP2, I-00133 Roma (IT).


(74) Agents: **MARCHI, Massimo** et al.; MARCHI & PARTNERS S.r.l., Via Pirelli, 19, I-20124 Milano (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,

[Continued on next page]

(54) Title: THIOPYROPHOSPHATE ORGANIC COMPOUNDS, METHOD FOR PREPARING THEREOF AND COMPOSITIONS CONTAINING THEM



(57) Abstract: Compound of general formula (I), where R, X and n have the meanings mentioned in the specification. The invention also relates to a method for preparing the compound of general formula (I) and a pharmaceutical composition containing the same.



RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

"Thiopyrophosphate organic compounds, method for preparing thereof
and compositions containing them"

* * * * *

Technical Field


5 This invention relates to a thiopyrophosphate organic compound, a
method for preparing thereof and a composition containing it.

More particularly the thiopyrophosphate organic compound according
to this invention has activating activity on $\gamma\delta$ T lymphocytes.

Background to the Invention

10 It is known that some organic compounds of pyrophosphoric acid,
both natural and synthetic, have activating activity on $\gamma\delta$ T
lymphocytes (Fournié et al., Microbes and Infection 2001, 3, 645-654).
Owing to this activity they are useful in the treatment of immunological
and allergic disorders (asthma, Chron's disease, multiple sclerosis)
15 (Bendelac et al., Nat. Rev. Immunol. 2001, 1, 177-185) and infectious
diseases (Wang et al., J. Clin. Invest. 2001, 108, 1349-1357) and
tumours (Girardi et al., Science 2001, 294, 605-609; Sicard et al., Mol.
Med. 2001, 7, 711-722).

Moreover U.S. 5,639, 653 describes the use of compounds of
20 formula



where

R is a straight or branched alkyl radical having from 1 to 4 carbon
atoms, or a straight or branched alkenyl radical having from 2 to 20
25 carbon atoms,
to stimulate the proliferation of $V\gamma 2V\delta 2$ T cells in mammals and in
particular for the treatment of lymphomas, leukaemia, leprosy, malaria,
AIDS, rheumatoid arthritis, ulcerous colitis and anaemia.

It is also known that other organic compounds of pyrophosphoric
30 acid, both natural and synthetic, behave as activators of $\gamma\delta$ T


- 2 -

lymphocytes. One example of these natural compounds is isopentenyl pyrophosphate (IPP) ("Isopentenyl Pyrophosphate, a Mycobacterial Non-peptidic Antigen, Triggers Delayed and Highly Sustained Signaling in Human $\gamma\delta$ T Lymphocytes without Inducing Down-modulation of T

5 Cell Antigen Receptor" Lafont, V. et al., J. Biol. Chem. 2001, 276, 15961-15967), while of the synthetic compounds known so far the most active appear to be the phosphohalodrin disclosed in U.S. 6,660,723 B1 and Espinosa, E. et al., (J. Biol. Chem. 2001, 276, 18337-18344)

The formulae of IPP and the above mentioned phosphohalodrin are

10 as follows:



Among the natural phosphoantigens initially identified in extracts from *Mycobacterium tuberculosis*, the compound (E)-4-hydroxy-3-methyl-2-butenyl pyrophosphate (an intermediate in the alternative

15 Rohmer metabolic pathway to mevalonate) extracted from *E.coli* is today the most active stimulant of $\gamma\delta$ 2 cells (Hintz, M. et al., Febs. Lett. 2001, 509, 317-322).

As a result of investigations of the relationship between structure and activity in a class of products having $\gamma\delta$ T lymphocyte activating activity,

20 it has been reported that two molecular components have to be present: an alkenyl chain and a pyrophosphonic group.

The alkenyl chain associated with the pyrophosphate group showing activating properties on $\gamma\delta$ T lymphocytes may have of from 3 to 5 carbon atoms and a double bond in 2 or 3 position (Morita, C. et al., J.

25 Immunol. 2001, 167, 36-41).


In other investigations an increase in activity due to addition of a halohydrin in C3 position or substitution of the double bond between C3

- 3 -

and C4 with a carbonyl group in the C4 position (Belmant, C. et al., FASEB J., 2000, 14, 1669-1670) has been observed. In these investigations it has been shown that it is also necessary for a hydrolysable phosphodiester bond to be present (Belmant, C. et al.,
5 FASEB J., 2000, 14, 1669-1670).


After activating compounds have been incubated with $\gamma\delta$ T cells it has been found that a molecule of free phosphate is produced.

Furthermore, in the literature there have been reported inconsistent data concerning the activity of bisphosphonate compounds in which the
10 P-CH₂-P sequence of bonds is present instead of the P-O-P sequence. In fact according to some authors substitution of the P-O-P sequence with the P-CH₂-P sequence gives rise to a drastic reduction in the ability to activate $\gamma\delta$ 2 T lymphocytes (Bioorg. & Med. Chem. Lett. 13, (2003) 1257-1260). Conversely, according to other authors compounds having
15 the sequence P-CH₂-P behave as $\gamma\delta$ 2 T lymphocyte inhibitors (Belmant et al., U.S. 6,624,151 B1).



The presence of the sequence C-O-P has also been investigated on account of its limited metabolic stability, which is crucial for possible
20 clinical applications in immunotherapy; structural modifications in which the sequence C-C-P is present instead of the sequence C-O-P have recently been investigated (Zgani, I. et al., J. Med. Chem. 2004, 47, 4600-4612) obtaining compounds in which the mean lifetime increases and preserves the activity of the corresponding metabolite.

- 4 -



Finally, some compounds of the thiopyrophosphate type which have the sequence C-S-P instead of the sequence C-O-P, analogues of isopentenyl pyrophosphate and derivatives (geranyl, farnesyl

5 pyrophosphates) are also known in the literature, but of these only their activity as inhibitors/substrates for the enzyme farnesyl/geranyl/undecaprenyl pyrophosphate synthetase have been evaluated (Phan, R.M.; Poulter, D., J. Org. Chem. 2001, 66, 6705-6710). In these experiments the presence of a thiopyrophosphate group instead of a

10 pyrophosphate group converts the substrates (FPP into FsPP) into inhibitors (Chen et al., J. Biol. Chem. 2002, 277, 7369-7376).

It has also been reported in the literature that the conversion of geranyl pyrophosphate into the corresponding thiopyrophosphate confers inhibiting activity on farnesyl pyrophosphate synthetase

15 (FFPase) of which it is a natural substrate (Dale Poulter et al., J. Am. Chem. Soc. 1991, 113, 4895; Organic Letters 2000, 15, 2287).

Antigen activity on $\gamma\delta$ T lymphocytes has never been evaluated in these thioderivatives.

Thus as the basis of the molecular mechanism of the $\gamma\delta$ TCR-phosphoantigens recognition is still unknown and it has not yet been


20 proven that this direct recognition is really responsible for activation, those skilled in the art do not yet have any means of foreseeing what effect changes in the structure of natural phosphoantigens might have on the function of $\gamma\delta$ T lymphocytes.

25 Now, surprisingly, a class of thiopyrophosphates which are chemically more stable than the corresponding pyrophosphates and which have activating activity on $\gamma\delta$ T lymphocytes has been found.

- 5 -

Description of the Invention

In a first aspect this invention relates to a compound of general formula (I):



5 in which

X is an oxygen atom, a sulphur atom or a covalent bond,

n is zero when X is a covalent bond and is 1, 2 or 3 when X is O or S,

R is (i) a straight or branched saturated or unsaturated aliphatic group having 1 to 9 carbon atoms, in which one hydrogen atom may be replaced by a halogen atom, a hydroxy group, a nitrile group, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group or a heterocyclic group, or
 10 (ii) a heterocyclic group, and

Cat⁺ is a physiologically acceptable organic or inorganic cation.

15 Preferred meanings of halogen are chlorine and fluorine.

Preferred meanings of aryl are benzene and pyridine.

Preferred meanings of heterocyclics are oxetane, dioxolane and tetrahydropyran.

Typical examples of inorganic cations are ammonium, alkali metals and alkaline earth metals. Preferred meanings of inorganic cations are NH₄⁺, Na⁺ and K⁺.
 20

Typical examples of organic cations are lysine, arginine, tromethamine, hydroxypyrrolidine, triethanolamine and N-methylglucamine.

25 The compounds of formula (I) according to the invention activate $\gamma\delta$ T lymphocytes with a potency which is at least similar to that of natural phosphoantigens. They also have the advantage that they are appreciably more stable to enzyme hydrolysis than natural

- 6 -

phosphoantigens.


This stability has been proved in an experiment in which the concentration of a IPP compound (isopentenyl pyrophosphate) and Compound 8 of this invention (isopentenyl thiopyrophosphate) in buffered solutions in the presence of alkaline phosphatase (Example 17) was monitored over time.

This makes the compounds of formula I according to this invention metabolically more stable and confers major therapeutic advantages upon them.

In a second aspect, this invention relates to a method for preparing a compound of formula (I) in which n, X, R and Cat⁺ have the above mentioned meanings, characterised in that an alcohol of formula (II)



in which n, X and R have the above mentioned meanings, is reacted in solid phase with a thiopyrophosphate of formula (III)



in which Cat⁺ has the above mentioned meanings.

Preferably Cat⁺ is a cation which is capable of solubilizing the compound (III) in organic solvents.


Typically Cat⁺ is a tetraalkyl ammonium group of formula (R'')₄N⁺ where R'' is an alkyl having 1 to 5 carbon atoms.

A preferred meaning of R'' is butyl.

The compound of formula (III) can be prepared according to known methods, such as, for example, the procedure described by Poulter, D.C. and Phan, R.M. (Organic Letters 2000, 2, 2287-2289) which result in the desired compound in 4 stages as shown in Scheme 1 below:

- 7 -

Scheme 1



Preferably the solid support used to carry out the reaction in solid
 5 phase according to this invention is polystyrene benzene sulphonyl
 chloride (PS-TsCl) having a low loading capacity (1.3 mmol/g).

Preferably the equivalents of the alcohol of formula (II) which are
 bound to the solid support according to the method of this invention
 range from 1 to 5 depending upon the nature of the R group.

10 In a preferred embodiment the alcohol of formula (II) is loaded onto
 the solid support in dichloromethane in the presence of pyridine or
 dimethylaminopyridine.

Advantageously the reaction time for the alcohol of formula (II) with
 the solid support ranges from 24 to 48 hours. Typically the progress of
 15 this reaction is monitored qualitatively by the bromophenol blue test, in
 which a small amount of resin is taken and 1,2-diaminoethane (5%
 solution in dimethyl formamide) is added thereto and binds to the sites
 on the resin which have not yet reacted. The resin is then washed and
 reacted with a solution of bromophenol blue which reacts with the
 20 amine groups. The blue colour of the resin pearls therefore shows that
 loading with the alcohol of formula (II) is not complete and that further
 alcohol of formula (II) must be loaded.

When the reaction is complete the excess of reactants is removed by
 filtration and subsequent washings. Advantageously these washings

- 8 -

are carried out with dichloromethane, dimethyl formamide, 3:1 tetrahydrofuran/water and finally tetrahydrofuran in succession.

A solution of thiopyrophosphate of formula (III) is then added to the solid support to which the alcohol of formula (II) had been bound.

5 In a preferred embodiment the solvent is acetonitrile.

Advantageously the amount of thiopyrophosphate of formula (III) added to the solid support having the alcohol of formula (II) bound thereto ranges from 0.8 to 1 equivalent.

Typically this stage is performed under stirring, for a time of
10 approximately 24 hours at ambient temperature.

When the reaction is complete the filtrate is collected and the thus obtained product is converted into the ammonium or sodium salt thereof with an ion exchange resin (DOWEX® 50-WX8-200) in a suitable form (NH_4^+ or Na^+ form).

15 The thus obtained products are analysed by LC-MS (negative or positive ESI) and are purified if necessary by precipitation and/or chromatography on a cellulose column.

As an alternative to the solid phase synthesis, the compounds of formula (I) of this invention may also be prepared in solution (see
20 Examples 7, 8 and 10-16) in a manner similar to that described by Poulter (J. Org. Chem. 2001, 66, 6705-6710).

The products obtained in this way are however less pure than those obtained in solid phase and require further purifications.

In a third aspect this invention relates to a pharmaceutical
25 composition comprising a compound of formula (I) of this invention and at least a physiologically acceptable carrier.

In literature, it has been reported that $\gamma\delta$ T lymphocytes show cytotoxic activity in response to cells infected with HIV virus (Poccia, F. et al., J. Immunol. 159, 6009-6017; Wallace, M. et al., Clin. Exp.
30 Immunol., 103, 177-184; Poccia, F. et al., J. Infect. Dis. 180, 858-861;

Agerberth, B. et al., Blood 96, 3086-3093) and show killer activity towards *Mycobacterium tuberculosis* (Dieli, F. et al., J. Infect. Dis. 184, 1082-1085; Dieli F. et al., Eur. J. Immunol. 30, 1512-1519) and to a number of myelomas and lymphomas (Wihelmm, M. et al., Blood 102, 200-206; Kunzmann, V. et al., Blood 96, 384-392; Fisch, P. et al., Eur. J. Immunol. 27, 3368-3379; Sicard, H.T. et al., Mol. Med. 7, 711-722).

Typical examples of pathological conditions which may derive benefit from treatment with a pharmaceutical composition according to this invention are therefore infections with HIV virus, infections with *Mycobacterium tuberculosis*, myelomas, lymphomas and some kinds of tumour such as kidney carcinoma (Viey, E. et al., J. Immunol. 174 (2005) 1338-1347).

Preferably the pharmaceutical compositions according to this invention are prepared in the form of suitable dosage forms comprising an effective dose of at least one compound of formula I and at least one physiologically acceptable inert ingredient suitable for oral, rectal, topical, intravenous, subcutaneous, intramuscular or intraperitoneal administration.

Examples of suitable dosage forms are tablets, capsules, coated tablets, granules, solutions and syrups for oral administration, medicated creams, ointments and plasters for topical administration, suppositories for rectal administration and sterile solutions for administration by injectable, aerosol or ophthalmic route.

The dosage forms may also contain other conventional ingredients such as: stabilising preservatives, surfactants, buffers, salts to regulate osmotic pressure, emulsifiers, sweeteners, colouring agents, flavourings and the like.

If required by particular treatments the pharmaceutical composition of this invention may contain other pharmacologically active ingredients which it is useful to administer at the same time.

- 10 -

The amount of compound of formula I in the pharmaceutical composition of this invention may vary over a wide range depending upon known factors such as, for example, the nature of the disease to be treated, the severity of the disease, the patient's body weight, the dosage form, the selected administration route, the number of administrations per day and the efficacy of the selected compound of formula I. However, the optimum amount may be determined easily and routinely by those skilled in the art.

Typically the amount of compound of formula I in the pharmaceutical composition of this invention is such as to ensure a level of administration of from 1 to 500 mg/kg/day.

The dosage forms of the pharmaceutical composition of this invention may be prepared according to techniques which are well known to pharmaceutical chemists, which include mixing, granulation, compression, dissolution, sterilisation and the like.

In a fourth aspect this invention relates to a method for activating $\gamma\delta$ T lymphocytes in mammals comprising contacting said lymphocytes with an effective amount of a compound of formula I.

Typically the said method is used for the treatment of human patients affected by HIV virus infections, *Mycobacterium tuberculosis* infections, myelomas, lymphomas and some forms of tumours such as kidney carcinoma.

Advantageously the said method comprises sampling a suitable amount of peripheral blood from a patient, contacting the said blood with a compound of formula I according to this invention for a sufficient time to stimulate the *ex vivo* proliferation of $\gamma\delta$ T lymphocytes, collecting the thus treated $\gamma\delta$ T cells and intravenously administering the same to the patient.

Experimental Part

The examples which follow describe the preparation of some

- 11 -


compounds of formula I according to this invention (Examples 1-16), the results of comparative tests (i) of stability to enzyme hydrolysis (Example 17) and (ii) the biological properties of compounds of formula I of this invention in comparison with the most representative natural $\gamma\delta$ T lymphocyte activator (IPP) (Example 18).

The analytical characterisations of the compounds have been carried out by means of a HPLC-MS Nebula system (Gilson-ThermoFinnigan), a Synergy Polar RP column (150 x 4.6; Phenomenex) or ODS3 column (150 x 4.6; GL Science) and nuclear magnetic resonance spectroscopy (^1H -NMR).

^1H -NMR spectra were recorded by means of a Bruker Avance 300 MHz instrument.

Example 1

S-(4-chlorobutyl) ester of the trisodium salt of thiodiphosphoric acid



Compound 1

27 mg of 4-chlorobutanol (0.248 mmol) in 0.6 ml of dichloromethane-pyridine (1:1) were added to 114 mg (0.165 mmol) of PS-TsCl resin (1.47 mmol/g) swelled in THF.

20 The reaction mixture was kept under stirring for 24 hours, the excess of reactant was filtered off and the resin was washed with dichloromethane (3 x 1 ml), dimethyl formamide (3 x 1 ml), 3:1 tetrahydrofuran/water (3 x 1 ml), and tetrahydrofuran (3 x 1 ml) in succession. This resin was monitored with the bromophenol blue test
25 until the blue colour of the resin disappeared.

Afterwards the resin was re-swelled in THF and tetrabutylammonium thiopyrophosphate (152 mg, 0.165 mmol) dissolved in acetonitrile (0.6 ml) was added. The reaction mixture was allowed to stand under stirring

- 12 -

for 24 hours. The reaction mixture was then filtered and the filtrate containing the product was passed over a DOWEX® (NH_4^+) resin to convert the tetrabutylammonium salt into ammonium salt by eluting with a mixture of 2% of 25 mMol NH_4HCO_3 in isopropanol (iPrOH).

5 The product obtained by lyophilisation of the eluate was purified of possible inorganic monothiophosphates or thiopyrophosphates by precipitation of these impurities with an iPrOH: CH_3CN : NH_4HCO_3 (0.1 M) mixture (4.5:2.5:3). After centrifuging the supernatant was recovered and again lyophilised.

10 To complete the purification, the product obtained from lyophilisation was further purified by chromatography on cellulose using an iPrOH: CH_3CN : NH_4HCO_3 (0.1 M) mixture (4.5:2.5:3) as an isocratic eluent. After lyophilisation the product (32 mg, yield: 61%) was characterised by LC-MS and ^1H -NMR analysis.


15 Analysis (ESI $^-$) = 283.2 (M-1).

^1H -NMR (300 MHz, D_2O): δ (ppm) 3.70 (2H, m), 2.92-2.85 (2H, m), 2.01-1.80 (4H, m).

Example 2

S-[2-(2-chloroethoxy)ethyl] ester of the trisodium salt of
thiodiphosphoric acid

20



Compound 2

Working in a way similar to that described in Example 1, 90 μl of 2-(2-chloroethoxy)ethanol (0.850 mmol) in 0.6 ml of dichloromethane (DCM)-pyridine (1:1) were added to 116 mg (0.170 mmol) of PS-TsCl resin (1.45 mmol/g) in tetrahydrofuran (THF).

25

The reaction mixture was allowed to stand under stirring for 24 hours, the excess reactant had been filtered off and the resin was washed with

- 13 -

DCM (3 x 1 ml), dimethyl formamide (DMF) (3 x 1 ml), 3:1 THF/water (3 x 1 ml) and THF (3 x 1 ml), in succession.

When the bromophenyl blue test was positive, this resin was re-swelled in THF and then tetrabutyl ammonium thiopyrophosphate (155 mg, 0.17 mmol) dissolved in acetonitrile (0.6 ml) was added.


After 24 hours the reaction mixture was filtered and the filtrate was passed over DOWEX® resin (NH₄⁺) for conversion into ammonium salt (eluent 25 mM of 2% NH₄HCO₃ in iPrOH). After lyophilisation the thus obtained product was purified from possible inorganic monothiophosphates and thiopyrophosphates by precipitating them out with an i-PrOH:CH₃CN:NH₄HCO₃ (0.1 M) mixture (4.5:2.5:3).

Analysis (ESI⁻) = 299.1 (M-1).

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.05-3.95 (4H, m), 3.92-3.84 (2H, m), 3.24-3.12 (2H, m).

Example 3

S-(2-cyclopropylethyl)ester of the trisodium salt of thiodiphosphoric acid



Compound 3

Working in a similar way to that described in Example 1, 71 mg of 2-cyclopropylethanol (0.825 mmol) in 0.6 ml of DCM-pyridine (1:1) were added to 114 mg (0.165 mmol) of PS-TsCl resin (1.450 mmol/g) in THF.


Then 151.3 mg (0.165 mmol) of tetrabutyl ammonium thiopyrophosphate (155 mg, 0.17 mmol) dissolved in acetonitrile (0.6 ml) were added. Purification, carried out by precipitation and chromatography on a cellulose column, yielded 40 mg of Compound 3 (yield: 77%).

Analysis (ESI⁻) = 261.2 (M-1).

- 14 -

Example 4

S-[2-(allyloxy)ethyl]ester of the trisodium salt of thiodiphosphoric acid



Compound 4

5 Working in a manner similar to that described in Example 1, 160 μ l of 2-(allyloxy)ethanol (1.5 mmol) in 0.8 ml of DCM-pyridine (1:1) were added to 206 mg (0.300 mmol) of PS-TsCl resin (1.45 mmol/g) in THF.

275.4 mg (0.3 mmol) of tetrabutylammonium thiopyrophosphate dissolved in acetonitrile (0.8 ml) were then added. The filtrate was
 10 passed over an ion exchange column (DOWEX® NH_4^+ resin). Purification was carried out by chromatography on a cellulose column with NH_4HCO_3 (25 mMol):iPrOH: CH_3CN eluent (1:2:1).


After lyophilisation 26.7 mg of Compound 4 were obtained (yield: 30%).

15 Analysis (ESI^-) = 277.2 (M-1)

^1H -NMR (300 MHz, D_2O): δ (ppm) 6.18-6.04 (1H, m), 5.48 (1H, d), 5.38 (1H, d), 4.22 (2H, d), 3.92 (2H, t), 3.62 (1H, d), 3.21-3.10 (2H, m).

Example 5

20 S-[(3-methoxyethane-3-yl)methyl]ester of the trisodium salt of thiophosphoric acid



Compound 5

Working in a manner similar to that described in Example 1, 144.5 μ l of (3-methoxyethane-3-yl)-methanol (1.5 mmol) in 0.8 ml of DCM-pyridine (1:1) were added to 200 mg (0.29 mmol) of PS-TsCl resin (1.45
 25 mmol/g) in THF.

- 15 -

293 mg (0.32 mmol) of tetrabutylammonium thiopyrophosphate dissolved in acetonitrile (0.8 ml) were then added. The filtrate was passed over an ion exchange column (DOWEX® NH₄⁺ resin). Purification was carried out by chromatography on a cellulose column with NH₄HCO₃ (25 mMol):iPrOH:CH₃CN eluent (1:2:1).


88.2 mg of Compound 5 were thus obtained (yield: 92%).

Analysis (ESI⁻) = 291.2 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.80 (2H, d), 4.55 (2H, d), 3.27 (2H, d), 1.51 (3H, s).

Example 6

S-(3-hydroxybutyl)ester of the trisodium salt of biodiphosphoric acid



Compound 6

Working in a manner similar to that described in Example 1, 52 µl of S-(3-hydroxy)butanol (0.6 mmol) in 0.8 ml of a solution of DCM and dimethylaminopyridine (DMAP) (35.4 mg, 0.29 mmol) were added to 200 mg (0.29 mmol) of PS-TsCl resin (1.45 mmol/g) in THF.

After 24 hours 293 mg (0.32 mmol) of tetrabutylammonium thiopyrophosphate dissolved in acetonitrile (0.8 ml) were added. The filtrate was passed over an ion exchange column (DOWEX® NH₄⁺ resin). Purification was carried out by chromatography on a cellulose column with NH₄HCO₃ (25 mMol):iPrOH:CH₃CN eluent (1:2:1).

79 mg of Compound 6 were thus obtained (yield: 86%).


Analysis (ESI⁻) = 279.0 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.12-4.07 (1H, m), 3.07-2.97 (1H, m), 2.90-2.84 (1H, m), 1.98-1.85 (2H, m), 1.30 (3H, d).

Example 7

- 16 -

S-(benzyl)ester of the trisodium salt of thiophosphoric acid



Compound 7

5 Tetrabutylammonium thiopyrophosphate (63 mg, 0.067 mmol) dissolved in 0.5 ml of acetonitrile was added at 0°C to a 3.56 µl (0.03 mmol) solution of benzyl bromide in acetonitrile (0.5 ml). The reaction mixture was kept under stirring at room temperature for 3 hours.

10 After removal of the solvent by evaporation at reduced pressure the crude material was purified as described in Example 1 (DOWEX® NH₄⁺ ion exchange column, precipitation and chromatography on a cellulose column) to yield 8.2 mg of a pure product (yield: 81%).


Analysis (ESI⁻) = 283.2 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 7.50 (2H, d), 7.42 (2H, t), 7.37-7.33 (1H, m), 4.13 (2H, d).

15

Example 8

S-(3-methyl-3-butenyl)ester of the trisodium salt of thiodiphosphoric acid



Compound 8

20 Working in a manner similar to that described by Poulter in J. Org. Chem. 2001, 66, 6705-6710, 11.1 mg of isopentenyl tosylate (0.046 mmol) and 100 mg of tetrabutylammonium thiopyrophosphate (0.106 mmol) were used. After purification (NH₄⁺ ion exchange column, precipitation and chromatography on a cellulose column) 7.1 mg of
25 Compound 8 were thus obtained (yield: 49%).


- 17 -

Analysis (ESI⁺) = 261.0 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.85 (2H, d), 3.04-2.97 (2H, m), 2.44 (2H, t), 1.77 (3H, s).

Example 9


- 5 S-[(*E*)-4-hydroxy-3-methyl-2-butenyl]ester of the trisodium salt of
thiodiphosphoric acid



Compound 9

- Compound 9 was obtained by working in a way similar to that
10 described by Amslinger et al. (J. Org. Chem. 2002, 67, 4590) except
that tetrabutylammonium thiopyrophosphate was used instead of
tetrabutylammonium pyrophosphate and the deprotection of the alcohol
group was carried out in a different way (see Scheme 2).

Scheme 2



15

- (a) toluene, reflux (23 hours),
(b) (1) DIBALH, CH₂Cl₂, -78 °C (2.5 hours),
(b) (2) 1 M NaOH/H₂O,

- 18 -

(c) p-TsCl, DMAP, CH₂Cl₂, 25 °C (3 hours),

(d) tris(tetra n-butylammonium) hydrogen diphosphate, CH₃CN, 25 °C (3 hours),

(e) NaCNBH₃, BF₃OEt₂, 25 °C (20 min).

5 After purification on an ion exchange column (eluent: 2% 25 mM NH₄HCO₃ in IsPrOH) 32 mg of pure product were isolated in the form of sodium salt.


Analysis (ESI⁻) = 276.97 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 5.57 (1H, t), 3.90 (2H, s), 3.48-3.40
10 (2H, m), 1.62 (3H, s).

Examples 10-16

The following compounds were obtained working in a way similar to that described in Example 7.

10) S-[2-(ethylthio)propyl]ester of the trisodium salt of thiodiphosphoric
15 acid




Compound 10

Analysis (ESI⁻) = 294.96 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 3.14-2.96 (2H, m), 2.81 (2H, t), 2.71
20 (2H, q), 2.12-2.04 (2H, m), 1.35 (3H, t).

11) S-(4-cyanobutyl)ester of the trisodium salt of thiodiphosphoric acid



Compound 11


Analysis (ESI⁻) = 276.1 (M-1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 2.84-2.72 (2H, m), 2.45 (2H, t), 1.80-
25 1.65 (4H, m).

12) S-(2-ethyl-1,3-dioxolanyl)ester of the trisodium salt of

- 19 -

thiodiphosphoric acid




Compound 12

Analysis (ESI⁻) = 295.1 (M-1)

- 5 ¹H-NMR (300 MHz, D₂O): δ (ppm) 4.98 (1H, t), 3.98-3.83 (4H, m), 2.87-2.77 (2H, m), 2.04-1.98 (2H, m).

13) S-(4-fluorobutyl)ester of the trisodium salt of thiodiphosphoric acid




Compound 13

- 10 LCMS Analysis (ESI⁺) = 295.1 (M+1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.55 (1H, t), 4.39 (1H, t), 2.84-2.73 (2H, m), 1.84-1.64 (4H, m).

14) S-(6-heptenyl)ester of the trisodium salt of thiodiphosphoric acid




- 15 Compound 14

LCMS Analysis (ESI⁺) = 291.1 (M+1)

¹H-NMR (300 MHz, D₂O): δ (ppm) 5.90-5.73 (1H, m), 4.96 (1H, d), 4.88 (1H, d), 2.78-2.70 (2H, m), 1.99-1.96 (2H, m), 1.61-1.56 (2H, m).

15) S-[ethyl-2-tetrahydro-2H-2-pyranyloxy]] ester of the trisodium salt of

- 20 thiodiphosphoric acid




Compound 15

- 20 -

LCMS Analysis (ESI⁺) = 239.1 (M+1-85)

¹H-NMR (300 MHz, D₂O): δ (ppm) 4.75 (1H, m), 3.94-3.81 (2H, m), 3.78-3.71 (1H, m), 3.55-3.49 (1H, m), 3.02-2.93 (2H, m), 1.73-1.70 (2H, m), 1.48-1.46 (2H, m).

- 5 16) S-(ethyl-2-cyclohexyl)ester of the trisodium salt of thiodiphosphoric acid



Compound 16


LCMS Analysis (ESI⁺) = 305.1 (M+1)

- 10 ¹H-NMR (300 MHz, D₂O): δ (ppm) 2.83-2.73 (2H, m), 1.64-1.43 (7H, m), 1.15-1.08 (4H, m), 0.86-0.78 (2H, m).


Example 17

Stability Tests

- 15 The following compounds were selected for the stability tests in alkaline aqueous solution in the presence of alkaline phosphatase (SIGMA Phosphatase, alkaline-Agarose from calf intestine-P0762):



IPP



Compound 8

20

Solution A:

pH 8 solution: TRIS-HCl buffer and 2 mM of MgCl₂;

Solution B:

comparison versus solution A: 2 mM isopentenyl pyrophosphate (IPP)

25 solution ;

Solution C:

2 mM isopentenyl thiopyrophosphate solution (Compound 8) of this

- 21 -

invention into Solution A,

Solution D:

Solution of phosphatase enzyme immobilised on a solid substrate (agarose), 50 biological units into 10 ml of Solution A.

5 Experimental conditions

20 μ l of Solution D were added to 0.5 ml of Solution B. The system was allowed to stand at ambient temperature under stirring. The solution was filtered to remove the enzyme and it was then analysed with HPLC-MS at predetermined time intervals (20, 30, 40, 50 and 60
10 minutes).

The same procedure was carried out with Solution C.

The results are shown in Table 1 below.

Table 1

	Percentage of non-hydrolysed compound					
	t = 0 min	t = 20 min	t = 30 min	t = 40 min	t = 50 min	t = 60 min
IPP	94%	48%	54%	-	-	27%
Compound 8	100%	90%	90%	90%	90%	90%

The results in Table 1 show that IPP degrades rapidly while isopentenyl
15 thiopyrophosphate (Compound 8) of this invention is very much more resistant to hydrolysis.

Example 18

Biological Tests

1. Test on peripheral blood mononucleate cells (PBMCs)

20 $\gamma\delta$ T lymphocyte activation was tested by an assay involving the production of cytokines such as $\text{TNF}\alpha$ and $\text{IFN}\gamma$ by the $\gamma\delta$ T lymphocytes of peripheral blood mononucleate cells (PBMCs) from healthy donors (Poccia, F. et al., The Journal of Immunology 1997, 159, 6009-6017).

25 Mononucleate cells (PBMCs) were isolated from the peripheral blood of healthy donors, cultured at 37°C on a complete medium comprising

- 22 -

RPMI 1640, 10% FCS, 1% L-glutamine, 1% penicillin-streptomycin in the presence of interleukin 2 (IL-2), T lymphocyte growth factor, and 5% CO₂ in a controlled humidity environment, and then stimulated with isopentenyl pyrophosphate (IPP 10 μ M) as a positive activation control and with various doses (10 μ M, 100 μ M and 1000 μ M) of compounds according to the invention, respectively.

Then it was performed a cytofluorimetric labelling using specific monoclonal antibodies (membrane labelling for the expansion and intracytoplasm labelling for the cytokines) and a cytofluorimetric measurement in order to establish the percentage of $\gamma\delta$ T cells producing TNF α and IFN γ (cytokine production assay).

The results are shown in Table 2 below, where "PBMC/IL-2" denotes the peripheral blood mononucleate cells from healthy donors in the presence of the complete substrate alone.

15

Table 2

Percentage increase in $\gamma\delta$ T lymphocytes producing TNF α and IFN γ

Compound	Experimental conditions	% increase in $\gamma\delta$ T lymphocytes producing:	
		INF γ	TNF α
	PBMC/IL-2 (blank)	2-8	4-11
IPP (std)	PBMC/IL-2/IPP (10 μ M)	100	100
Compound 1	PBMC/IL-2/compound 1 (10 μ M)	131	81
	PBMC/IL-2/compound 1 (100 μ M)	94	127
	PBMC/IL-2/compound 1 (1000 μ M)	132	81.5
Compound 2	PBMC/IL-2/compound 2 (10 μ M)	56.4	60.4
	PBMC/IL-2/compound 2 (100 μ M)	67	71.8
	PBMC/IL-2/compound 2 (1000 μ M)	97.3	76.5
Compound 3	PBMC/IL-2/compound 3 (10 μ M)	-	49.5
	PBMC/IL-2/compound 3 (100 μ M)	-	123
	PBMC/IL-2/compound 3 (1000 μ M)	-	158.4

Compound 4	PBMC/IL-2/compound 4 (10 μ M)	-	70.7
	PBMC/IL-2/compound 4 (100 μ M)	-	130.4
	PBMC/IL-2/compound 4 (1000 μ M)	-	299.3
Compound 5	PBMC/IL-2/compound 5 (10 μ M)	-	48
	PBMC/IL-2/compound 5 (100 μ M)	-	229
	PBMC/IL-2/compound 5 (1000 μ M)	-	337
Compound 6	PBMC/IL-2/compound 6 (10 μ M)	-	40
	PBMC/IL-2/compound 6 (100 μ M)	-	114
	PBMC/IL-2/compound 6 (1000 μ M)	-	310
Compound 7	PBMC/IL-2/compound 7 (10 μ M)	82	86
	PBMC/IL-2/compound 7 (100 μ M)	112	116
	PBMC/IL-2/compound 7 (1000 μ M)	95	87
Compound 8	PBMC/IL-2/compound 8 (10 μ M)	21	39
	PBMC/IL-2/compound 8 (100 μ M)	86.5	92.6
	PBMC/IL-2/compound 8 (1000 μ M)	182	174.3
Compound 9	PBMC/IL-2/compound 9 (10 μ M)	-	82.3
	PBMC/IL-2/compound 9 (100 μ M)	-	175
	PBMC/IL-2/compound 9 (1000 μ M)	-	464
Compound 10	PBMC/IL-2/compound 10 (10 μ M)	-	-
	PBMC/IL-2/compound 10 (100 μ M)	-	-
	PBMC/IL-2/compound 10 (1000 μ M)	-	-

- = not tested

The data in Table 2 shows that all the compounds of this invention increase the number of $\gamma\delta$ T cells producing cytokines (activation of $\gamma\delta$ T lymphocytes); in particular Compound 9 has an activity similar to that of natural antigen IPP under the same experimental conditions (i.e. at a concentration of 10 μ M), and a very clear increase at 100 and 1000 μ M.

2. Peripheral blood mononucleate cell (PBMC) cellular expansion assay

The effect of the compounds of this invention on the expansion of $\gamma\delta$ T lymphocytes was investigated through an assay carried out on $\gamma\delta$ T

- 24 -

lymphocytes originating from the peripheral blood mononucleate cells from healthy donors (PBMCs).

The PBMCs were separated by centrifuging (Ficoll) on whole blood from samples (residual samples) from 7 healthy donors.

5 After the initial percentage of $V\gamma 9V\delta 2$ cells from each donor had been evaluated by labelling with an anti-Vd2-FITC antibody and cytofluorimetric analysis, the cells were placed on 24-well plates (10^6 cells/ml) in complete medium (having the composition mentioned in section 1 of this example) in the presence of Compound 9 of this
10 invention ($20\ \mu\text{M}$). In control experiments the cells were treated with IPP at the same concentrations and under the same experimental conditions.

On the tenth day of culture the cells were recovered and counted by means of a living count with Trypan Blue, and labelled with the same
15 anti-Vd2-FITC antibody, and finally tested by cytofluorimetry to evaluate the percentage of $V\gamma 9V\delta 2$ cells.

The absolute number of $V\gamma 9V\delta 2$ cells was calculated using the following formula:

No. of $V\gamma 9V\delta 2$ cells = (total absolute no. of cells after expansion x % of
20 $V\gamma 9V\delta 2$ cells after expansion) /100.

The expansion index was calculated using the ratio between the absolute number of $V\gamma 9V\delta 2$ cells after expansion and the absolute number of initial $V\gamma 9V\delta 2$ cells (Poccia, F. et al., J. Immunol., 1997, 159: 6009-6017).

25 The results obtained are shown in Table 3 below and in Figure 1.

Table 3

Donor	Expansion Index	
	Compound 9 ($20\ \gamma\text{M}$)	IPP ($20\ \gamma\text{M}$)
A	129.28	5.41
B	80.96	2.42

- 25 -

C	51.30	11.11
D	59.10	2.81
E	624.02	72.92
F	35.37	23.87
G	42.09	3.35

3. Test on $\gamma\delta$ T cell lines; production of $\text{TNF}\alpha$ and EC_{50} test according to E. Espinosa et al. (J. Biol. Chem. 2001, 276, 18337-44)

3.1 Growth of the $\gamma\delta$ T lymphocyte line

5 A buffy coat from a healthy donor with a high basal percentage of $\gamma\delta$ T lymphocytes (approximately 6%) was selected for growth of the $\gamma\delta$ T lymphocyte lines.

The PBMCs were separated out and cultured at a concentration of 1×10^6 cells/ml in the presence of IPP (160 ng/ml) and IL-2 (100 U/ml).

10 After 7 days incubation at 37°C with 5% CO_2 , 3 ml of medium were sampled and replaced with the same amount of fresh medium enriched with IL-2 (final concentration 100 U/ml).

After a further 7 days in the incubator an aliquot of the cultured cells was taken to label the membrane and measure the percentage of $\gamma\delta$ T cells obtained from the expansion.

15 In the specific instance a cell population of 85% of $\gamma\delta 2$ positive T cells was obtained.

This cell line was then used to evaluate the production of $\text{TNF}\alpha$ following stimulation of the cells with the compounds under investigation, using an ELISA test.

20 3.2 ELISA test for the production of $\text{TNF}\alpha$

In the ELISA test there were used cells from the line produced as disclosed above in a concentration of 2.5×10^5 cells/ml (5×10^4 cells/well).

25 The cells were then stimulated with the compounds under investigation and with isopentenyl pyrophosphate (IPP) as a reference

- 26 -

at scalar doses.

After 24 hours the supernatants from the wells containing the stimulated cells were sampled and the ELISA test was carried out using the "Human TNF α Screening Set" kit (Endogen). The kit provides for treatment with an anti-TNF α biotinylate polyclonal antibody, the addition of peroxidase conjugated with streptavidine and quantitative determination using a chromogenic substrate. The plates were read spectrophotometrically at 450 nm.

Each compound was tested in duplicate.

The results obtained were then analysed using a specific analysis program (Graph Pad Prism) and yielded the EC₅₀ for the compounds under investigation (Table 4).

Table 4

EC₅₀ values obtained using the ELISA test for the production of TNF α in the $\gamma\delta$ T lymphocyte line


Compound	EC ₅₀ (μ M)
IPP	5.92
1	100
2	0.39
3	13
4	10
5	14
6	75
7	55
8	3.75
9	0.0048
10	0.055

Table 3 shows that the EC₅₀ values for the compounds in Examples 10 and 9 are equal to 100 and 1000 times the EC₅₀ for IPP, respectively.

- 27 -

CLAIMS

1. A compound of general formula (I):



(I)

5 in which

X is an oxygen atom, a sulphur atom or a covalent bond,
n is zero when X is a covalent bond and is 1, 2 or 3 when X is O or S,

10 R is (i) a straight or branched saturated or unsaturated aliphatic group having 1 to 9 carbon atoms, in which one hydrogen atom may be replaced by a halogen atom, a hydroxy group, a nitrile group, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group or a heterocyclic group, or
(ii) a heterocyclic group, and


15 Cat⁺ is a physiologically acceptable organic or inorganic cation.

2. A compound of formula (I) according to Claim 1, characterised in that the halogen atom is chlorine or fluorine.
3. A compound of formula (I) according to Claim 1, characterised in that the aryl group is selected from the group comprising benzene and pyridine.
- 20 4. A compound of formula (I) according to Claim 1, characterised in that the hetrocyclic group is selected from the group comprising 3-methyloxetane, dioxolane and tetrahydropyran.
5. A compound of formula (I) according to any one of Claims 1 to 4, characterised in that Cat⁺ is an inorganic cation selected from ammonium, alkali metals and alkaline earth metals.
- 25 6. A compound of formula (I) according to any one of Claims 1 to 4,

- 28 -

characterised in that Cat⁺ is an organic cation selected from lysine, arginine, tromethamine, hydroxyethylpyrrolidine, triethanolamine and N-methylglucamine.

7. A method for preparing a compound of formula (I)



(I)

in which

X is an oxygen atom, a sulphur atom or a covalent bond,


n is zero when X is a covalent bond and is 1, 2 or 3 when X is O or S,

R is (i) a straight or branched saturated or unsaturated aliphatic group having 1 to 9 carbon atoms, in which one hydrogen atom may be replaced by a halogen atom, a hydroxy group, a nitrile group, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group or a heterocyclic group, or
(ii) a heterocyclic group, and

Cat⁺ is a physiologically acceptable organic or inorganic cation, characterised in that an alcohol of formula (II)



where n, X and R have the above mentioned meanings, is reacted in solid phase with a thiopyrophosphate of formula (III)



(III)


where Cat⁺ has the above mentioned meanings.

8. A method according to Claim 7, characterised in that Cat⁺ is a

- 29 -

tetraalkyl ammonium group of formula $(R'')_{4N}^{+}$ where R'' is an alkyl having 1 to 5 carbon atoms.

9. A method according to Claim 7 or 8, characterised in that the solid support used to carry out the reaction in solid phase according to this invention is polystyrene benzene sulphonyl chloride (PS-TsCl) having a low loading capacity (1.3 mmol/g).
10. A method according to any one of Claims 7 to 9, characterised in that the equivalents of alcohol of formula (II) which are bound to the solid support range from 1 to 5 depending upon the nature of the R group.
11. A pharmaceutical composition comprising a compound of formula (I)




(I)

- in which
- X is an oxygen atom, a sulphur atom or a covalent bond,
- n is zero when X is a covalent bond and is 1, 2 or 3 when X is O or S,
- R is (i) a straight or branched saturated or unsaturated aliphatic group having 1 to 9 carbon atoms, in which one hydrogen atom may be replaced by a halogen atom, a hydroxy group, a nitrile group, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group or a heterocyclic group, or
- (ii) a heterocyclic group, and
- Cat⁺ is a physiologically acceptable organic or inorganic cation, and at least one physiologically acceptable carrier.
12. A method for activating mammalian $\gamma\delta$ T lymphocytes characterised in that it comprises contacting the said lymphocytes with an

- 30 -

effective amount of a compound of formula I



(I)


in which

5 X is an oxygen atom, a sulphur atom or a covalent bond,
n is zero when X is a covalent bond and is 1, 2 or 3 when X is O or S,

10 R is (i) a straight or branched saturated or unsaturated aliphatic group having 1 to 9 carbon atoms, in which one hydrogen atom may be replaced by a halogen atom, a hydroxy group, a nitrile group, a cycloalkyl group having 3 to 6 carbon atoms, an aryl group or a heterocyclic group, or
(ii) a heterocyclic group, and

Cat⁺ is a physiologically acceptable organic or inorganic cation.

- 15 13. A method according to Claim 12, characterised in that it comprises
- sampling a suitable amount of peripheral blood from a patient,
 - contacting the said blood with a compound of formula I for sufficient time to stimulate *ex vivo* proliferation of $\gamma\delta$ T lymphocytes,
 - 20 - collecting the thus treated $\gamma\delta$ T cells, and
 - administering them to the patient by intravenous route.



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/051896

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07F9/165 A61K31/6615 A61P35/00 A61P29/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07F A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PHAN, RICHARD M. ET AL: "Synthesis of (S)-Isoprenoid Thiodiphosphates as Substrates and Inhibitors" JOURNAL OF ORGANIC CHEMISTRY, 66(20), 6705-6710 CODEN: JOCEAH; ISSN: 0022-3263, 2001, XP002432931 cited in the application abstract; compounds ISPP, DMASPP	1-4, 11
A	ESPINOSA ET AL: "Y2K+1 state-of-the-art on non-peptide phosphoantigens, a novel category of immunostimulatory molecules" MICROBES AND INFECTION, vol. 3, 2001, pages 645-654, XP002432932 cited in the application the whole document	1-13

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 May 2007

Date of mailing of the international search report

12/06/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Eberhard, Michael

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/051896

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/070921 A (INNATE PHARMA [FR]; ROMAGNE FRANCOIS [FR]; LAPLACE CATHERINE [FR]) 28 August 2003 (2003-08-28) abstract; examples (I),(II) -----	1-13
A	WO 2005/102385 A (INNATE PHARMA [FR]; TIOLLIER JEROME [FR]) 3 November 2005 (2005-11-03) abstract; examples (I)-(III) -----	1-13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2007/051896

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 12 and 13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/051896

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03070921	A	28-08-2003	AU 2003229834 A1	09-09-2003
			CA 2475437 A1	28-08-2003
			EP 1476540 A1	17-11-2004
			FR 2836483 A1	29-08-2003
			JP 2005517440 T	16-06-2005
			US 2005196385 A1	08-09-2005
<hr/>				
WO 2005102385	A	03-11-2005	AU 2005235271 A1	03-11-2005
			EP 1761278 A1	14-03-2007
<hr/>				